Compare NBIX & PAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | PAG |
|---|---|---|
| Founded | 1992 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 14.2B |
| IPO Year | 1996 | 1996 |
| Metric | NBIX | PAG |
|---|---|---|
| Price | $155.12 | $219.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 8 |
| Target Price | $180.91 | ★ $183.50 |
| AVG Volume (30 Days) | ★ 1.1M | 264.4K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.26% |
| EPS Growth | ★ 41.95 | 2.84 |
| EPS | 3.30 | ★ 7.52 |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $0.83 |
| Revenue Next Year | $13.14 | $4.31 |
| P/E Ratio | $47.95 | ★ $29.10 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $140.12 |
| 52 Week High | $186.12 | $227.00 |
| Indicator | NBIX | PAG |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 60.49 |
| Support Level | $153.96 | $216.14 |
| Resistance Level | $161.29 | $220.78 |
| Average True Range (ATR) | 3.58 | 2.69 |
| MACD | 0.90 | -0.89 |
| Stochastic Oscillator | 77.56 | 60.84 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Penske Automotive Group operates in 19 US states and overseas. It has about 150 US and Puerto Rico light-vehicle stores as well as 217 franchised dealerships overseas, primarily in the United Kingdom but also in Australia, Germany, Italy, and Japan. The company is the third-largest US publicly traded dealership in terms of light-vehicle revenue and sells more than 40 brands, with over 90% of retail automotive revenue coming from luxury and import names. Other segments are service and finance and insurance. The firm's Premier Truck Group owns 45 truck dealerships selling mostly Freightliner and Western Star brands, and Penske owns 15 used-vehicle stores, mostly in the US and UK under the CarShop (US) and Sytner Select (UK) brands. Penske is based in Bloomfield Hills, Michigan.